TP53 mutation screening for patients at risk of myeloid malignancy.
medRxiv
; 2024 Feb 08.
Article
in En
| MEDLINE
| ID: mdl-38410480
ABSTRACT
There is increasing recognition of the risk of developing therapy-related myeloid malignancy, including after cellular therapy. While retrospective studies have implicated pre-existing TP53 mutated hematopoietic clones as a common causative mechanism, no prospective screening to identify those patients at greatest risk is currently possible. We demonstrate that ultradeep DNA-sequencing prior to therapy may be used for discovery of TP53 mutations that are subsequently associated with malignancy.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
MedRxiv
Year:
2024
Document type:
Article
Country of publication:
United States